MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH /...


MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that it will terminate the Phase 2 clinical trial of MN-001 in NASH and NAFLD with hypertriglyceridemia early based on the significant positive results from an interim analysis. MN-001 significantly reduced mean serum triglycerides, a primary endpoint, from 260.1 mg/dL before treatment to 185.2 mg/dL after eight weeks of treatment .



from Biotech News